Hou Chun-Cheng, Hung Su-Li, Kao Shu-Huei, Chen Tso Hsiao, Lee Horng-Mo
Department of Internal Medicine, Taipei Medical University-Wang Fang Hospital, Taipei, Taiwan.
Ann N Y Acad Sci. 2005 May;1042:235-45. doi: 10.1196/annals.1338.026.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently used as analgesics. They inhibit cyclooxygenases (COX), preventing the formation of prostaglandins, including prostacyclin and thromboxane. A serious side effect of COX-1 and COX-2 inhibitors is renal damage. To investigate the molecular basis of the renal injury, we evaluated the expression of the stress marker, heme oxygenase-1 (HO-1), in celecoxib-stimulated mesangial cells. We report here that a COX-2 selective NSAID, celecoxib, induced a concentration- and time-dependent increase of HO-1 expression in glomerular mesangial cells. Celecoxib-induced HO-1 protein expression was inhibited by actinomycin D and cycloheximide, suggesting that de novo transcription and translation are required in this process. N-acetylcysteine, a free radical scavenger, strongly decreased HO-1 expression, suggesting the involvement of reactive oxygen species (ROS). Celecoxib-induced HO-1 expression was attenuated by pretreatment of the cells with SP 600125 (a specific JNK inhibitor), but not SB 203580 (a specific p38 MAPK inhibitor), or PD 98059 (a specific MEK inhibitor). Consistently, celecoxib activated c-Jun N-terminal kinase (JNK) as demonstrated by kinase assays and by increasing phosphorylation of this kinase. N-acetylcysteine reduced the stimulatory effect of celecoxib on stress kinase activities, suggesting an involvement of JNK in HO-1 expression. On the other hand, LY 294002, a phosphatidylinositol 3-kinase (PI-3K)-specific inhibitor, prevented the enhancement of HO-1 expression. This effect was correlated with inhibition of the phosphorylation of the PDK-1 downstream substrate Akt/protein kinase B (PKB). In conclusion, our data suggest that celecoxib-induced HO-1 expression in glomerular mesangial cells may be mediated by ROS via the JNK-PI-3K cascade.
非甾体抗炎药(NSAIDs)常被用作镇痛药。它们抑制环氧化酶(COX),从而阻止包括前列环素和血栓素在内的前列腺素的形成。COX - 1和COX - 2抑制剂的一个严重副作用是肾损伤。为了研究肾损伤的分子基础,我们评估了在塞来昔布刺激的系膜细胞中应激标志物血红素加氧酶 - 1(HO - 1)的表达。我们在此报告,一种COX - 2选择性NSAID塞来昔布,在肾小球系膜细胞中诱导了HO - 1表达的浓度和时间依赖性增加。塞来昔布诱导的HO - 1蛋白表达被放线菌素D和环己酰亚胺抑制,这表明在此过程中需要从头转录和翻译。自由基清除剂N - 乙酰半胱氨酸强烈降低HO - 1表达,表明活性氧(ROS)参与其中。用SP 600125(一种特异性JNK抑制剂)预处理细胞可减弱塞来昔布诱导的HO - 1表达,但用SB 203580(一种特异性p38 MAPK抑制剂)或PD 98059(一种特异性MEK抑制剂)预处理则无此作用。一致地,激酶测定和该激酶磷酸化增加表明塞来昔布激活了c - Jun N末端激酶(JNK)。N - 乙酰半胱氨酸降低了塞来昔布对应激激酶活性的刺激作用,表明JNK参与了HO - 1表达。另一方面,磷脂酰肌醇3 - 激酶(PI - 3K)特异性抑制剂LY 294002阻止了HO - 1表达的增强。这种作用与抑制PDK - 1下游底物Akt/蛋白激酶B(PKB)的磷酸化相关。总之,我们的数据表明,塞来昔布在肾小球系膜细胞中诱导的HO - 1表达可能由ROS通过JNK - PI - 3K级联介导。